SOUTH SAN FRANCISCO, Calif., June 23, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK ) today announced presentations at the Cure SMA 2017 Annual SMA Conference from June 29 - July 2, 2017 in Orlando, FL. In an oral presentation on July 1, Stacy Rudnicki, M.D., Director, Clinical Research and Development at Cytokinetics will present data relating to patient baseline characteristics and the reasons for patient screen failure from the first cohort of the Phase 2 clinical trial of CK-2127107 in spinal muscular atrophy (SMA). Additionally, Dr. Rudnicki will participate in a panel discussion on SMA drugs in development on July 1. During a poster session on June 30, Eva Chin, Ph.D., Director, Pharmacology, Muscle Biology & Therapeutics at Cytokinetics will present preclinical data for CK-2127107 in mouse models of SMA.
Oral Presentation
Date : Saturday, July 1, 2017 Location : Ballroom of America B Session : SMA Therapy Development Time : 10:00 AM Title : Clinical Trial Update of CY 5021: CK-2127107, a Selective Activator of the Fast Skeletal Muscle Troponin Complex, for the Potential Treatment of Spinal Muscular Atrophy Presenter : Stacy Rudnicki, M.D., Director, Clinical Research and Development, Cytokinetics
Panel Discussion
Date : Saturday, July 1, 2017 Location : Fantasia Ballroom, Contemporary Hotel, Disney World Session : Research Q&A Session Time : 1:50 PM Title : Panel on SMA Drugs in Development Speaker : Stacy Rudnicki, M.D., Director, Clinical Research and Development, Cytokinetics
Poster Presentation
Date : Friday, June 30, 2017 Location : Ballroom of America A Session : Poster Session B Time : 12:45-2:45 PM Poster Number : 50 Title : The Fast Skeletal Muscle Troponin Activator, CK-2127107, Improves Muscle Function in Mouse Models of Spinal Muscular Atrophy Poster Presenter : Eva Chin, Ph.D., Director, Pharmacology, Muscle Biology & Therapeutics, Cytokinetics
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv , a fast skeletal muscle troponin activator (FSTA). Tirasemtiv is the subject of VITALITY-ALS, an international Phase 3 clinical trial in patients with ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics is preparing for the potential commercialization of tirasemti v in North America and Europe and has granted an option to Astellas for development and commercialization in other countries. Cytokinetics is collaborating with Astellas to develop CK-2127107, a next-generation FSTA. CK-2127107 has been granted orphan drug designation by the FDA for the potential treatment of SMA. CK-2127107 is the subject of two ongoing Phase 2 clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease. Cytokinetics is collaborating with Amgen Inc. (“Amgen”) to develop omecamtiv mecarbil , a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of GALACTIC-HF, an international Phase 3 clinical trial in patients with heart failure. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Astellas holds an exclusive worldwide license to develop and commercialize CK-2127107. Licenses held by Amgen and Astellas are subject to Cytokinetics' specified co-development and co-commercialization rights. For additional information about Cytokinetics, visit http://www.cytokinetics.com/ .
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities; the design, results, significance and utility of preclinical study results; and the properties and potential benefits of Cytokinetics’ drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trial results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy, the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Astellas’ decisions with respect to the design, initiation, conduct, timing and continuation of development activities for CK-2127107; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics’ collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.
Contact: Cytokinetics Diane Weiser Vice President, Corporate Communications, Investor Relations (415) 290-7757
